


# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA




**UCSF** Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research





# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA



Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research



# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA



Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research



# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA



**UCSF** Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research



# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA



**UCSF** Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research



# Stem Cell Research Update: Parkinson's Disease

Dan Lim, MD, PhD  
Assistant Professor, UCSF  
Director of Restorative Neurosurgery, UCSF  
Staff Neurosurgeon, SFVA




Eli and Edythe Broad Center  
of Regeneration Medicine  
and Stem Cell Research




In Parkinson's disease (PD), there is a loss of neurons that connect from a part of the brain called the substantia nigra to the **putamen**.

These neurons normally produce the neurochemical **dopamine** for the putamen.





Thus, in PD, *there is a loss of dopamine in the putamen.*



Normal FD-PET scan



Loss of dopamine in  
Parkinson's disease



***Transplanted cells may have advantages to medical therapy....***

may provide a continuous source of dopamine

may provide dopamine in a more physiologically relevant context

***But past experience with transplantation gave mixed results.***

transplanted cells were from donor fetal brains

improvements were marginal

15-50% of patients had unwanted side effect of dyskinesias




***Why the new hope?***

## *The promise of embryonic stem (ES) cells....*

Limitations of past studies included variability of types of cells grafted and the difficulty in obtaining sufficient numbers of cells.

A more pure population of dopamine neurons may reduce side effects.

*ES cells can produce essentially unlimited numbers of dopamine neurons.*




## ***Important considerations....***

**Safety.** There is a potential risk of tumors from any ES cell-derived therapy. There is also a risk of immune rejection.


**Long term efficacy.** Some reports suggest that transplanted cells may also become sick from PD after several years.


Is the putamen the best target for transplantation?





CALIFORNIA  
INSTITUTE FOR REGENERATIVE MEDICINE  
*The State Stem Cell Agency*






Lim Lab (UCSF)

Epigenetics of neural stem cells

*(How do adult neural stem cells “remember” how to make the many different types of neurons and support cells in the brain?)*




Xianmin Zeng (Buck  
Institute)

CIRM Disease team grant  
application leader

Development of dopamine  
neurons from human  
embryonic stem cells



CALIFORNIA  
INSTITUTE FOR REGENERATIVE MEDICINE  
*The State Stem Cell Agency*




Dr Krtolica (StemLifeLine)

Production of clinical grade  
cells for human  
transplantation.



CALIFORNIA  
INSTITUTE FOR REGENERATIVE MEDICINE  
*The State Stem Cell Agency*




Dr. Quik (Parkinson's  
Institute)

Preclinical testing of cell  
transplantation efficacy and  
safety



CALIFORNIA  
INSTITUTE FOR REGENERATIVE MEDICINE  
*The State Stem Cell Agency*




Lim, Marks, Aminoff  
(UCSF)

Preclinical Data Review,  
IND filing, clinical trial  
design




CALIFORNIA  
INSTITUTE FOR REGENERATIVE MEDICINE  
*The State Stem Cell Agency*



Larson, Starr, Martin  
(UCSF)

Interventional MRI for  
neurosurgery



Susan Heath, RN

Monica Volz, RN

Robin Taylor, RN

Paul Larson, MD

Phil Starr, MD, PhD

Bill Marks, MD

Michael Aminoff, MD

Jill Ostrem, MD

Alec Glass, MD

Xianmin Zeng (Buck Institute)

*Sandler Family Foundation, NIH DP2 New Innovator Award, Sontag Foundation,  
VA Merit Award, CIRM, NCIRE, CTSI/UCSF, REAC/UCSF, NREF/ACS*